Literature DB >> 2720198

Determinants for serum 1,25-dihydroxycholecalciferol in primary hyperparathyroidism.

L Mosekilde1, P Charles, P Lindegreen.   

Abstract

Serum levels of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), 25-hydroxyvitamin D3 (25(OH)D3), C-terminal immunoreactive PTH (iPTH), calcium and phosphate, and endogenous creatinine clearance (Clcr) were measured in 34 patients with primary hyperparathyroidism. Clcr ranged from 13 to 161 ml/min (mean 72). S-iPTH was elevated in 82% of the patients and correlated positively to serum calcium (r = 0.74, P less than 0.001) and inversely to Clcr (r = -0.50, P less than 0.02). S-25(OH)D3 was reduced in 28% of the patients and depended on regular multivitamin supplementation (P less than 0.005). S-1,25(OH)2D3 was increased in 26% of the patients and decreased in 9%. It was positively correlated to S-25(OH)D3 (r = 0.39, P less than 0.05) and Clcr (r = 0.42, P less than 0.02) and inversely to serum levels of calcium (r = -0.39, P less than 0.05), phosphate (r = -0.42, P less than 0.02) and iPTH (r = -0.40, P less than 0.05). Multiple regression analysis revealed a positive correlation to 25(OH)D3 when Clcr was taken into account and to Clcr when S-25(OH)D3 was taken into account. When both variables were considered no significant partial correlations were found between S-1,25(OH)2D3 and serum calcium, phosphate and PTH, respectively. It is concluded that serum levels of 25(OH)D3 and renal function are the main determinants for S-1,25(OH)2D3 in primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2720198     DOI: 10.1016/0169-6009(89)90006-8

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  5 in total

1.  Effects of a short course of oral phosphate treatment on serum parathyroid hormone(1-84) and biochemical markers of bone turnover: a dose-response study.

Authors:  K Brixen; H K Nielsen; P Charles; L Mosekilde
Journal:  Calcif Tissue Int       Date:  1992-10       Impact factor: 4.333

2.  Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study.

Authors:  Charlotte L Mollerup; Peter Vestergaard; Vibe Gedsø Frøkjaer; Leif Mosekilde; Peer Christiansen; Mogens Blichert-Toft
Journal:  BMJ       Date:  2002-10-12

3.  Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism.

Authors:  Emily M Stein; David W Dempster; Julia Udesky; Hua Zhou; John P Bilezikian; Elizabeth Shane; Shonni J Silverberg
Journal:  Bone       Date:  2010-10-13       Impact factor: 4.398

4.  1,25-dihydroxyvitamin D and the vitamin D receptor gene polymorphism Apa1 influence bone mineral density in primary hyperparathyroidism.

Authors:  Monika H E Christensen; Ellen M Apalset; Yngve Nordbø; Jan Erik Varhaug; Gunnar Mellgren; Ernst A Lien
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

5.  Total and free vitamin D metabolites in patients with primary hyperparathyroidism.

Authors:  L Meng; C Su; S A Shapses; X Wang
Journal:  J Endocrinol Invest       Date:  2021-07-19       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.